Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-491
¥ million (year-on-year change in operating loss)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Financial Results PresentationFiscal year ending March 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales212 Millions of yen+21.1%
Operating profit-1,081 Millions of yen
Ordinary income-1,028 Millions of yen
Net income-1,022 Millions of yen
Selling, general and administrative expenses1,211 Millions of yen
Gross Profit Margin61.3% (year-on-year change in percentage points: not disclosed)
Operating profit margin-509.9% (year-on-year change in percentage points: not disclosed)
Full-year earnings forecast
Fiscal year ending March 2027
Net SalesNot disclosed
Operating loss-1,430
Ordinary loss-1,400
Net loss attributable to owners of the parent-1,390
What the company explained in this material
Key points of the Q&AKey questions raised by investors at the briefing and the company's answers
Not disclosed (responses to advance questions are scheduled to be provided in the earnings presentation video)Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in CDMO business sales
- Increase in R&D expenses300 Millions of yen
- Increase in personnel expenses115 Millions of yen
- Increase in non-operating income45 Millions of yen
- Decrease in non-operating expenses58 Millions of yen
New initiatives
- Revision of the ReHeart earnings forecast after the drug price is determined
- Acceleration of joint catheter development with 朝日インテック
- Launch of research and development on an arrhythmia risk analysis platform with Institute of Science Tokyo
- Preparation for physician-initiated clinical trials for the YS series
- Research and development of large-scale cell culture technology using a METI subsidy for regenerative medicine CDMO operations
- Launch of process development operations at a pilot-scale plant
Key KPIsA metric the company considers important as a management benchmark.
- Cash and deposits ratio76.1 ％Year on year against the same period last year-7.4 percentage points
- Equity ratio91.6 ％Year on year against the same period last year-4.5 percentage points
- Number of products subject to conditional and time-limited approval75 Example
Segment results
Not disclosed (only an explanation that CDMO business sales increased)Financial targets
Not disclosed (equity ratio of 91.6% is an actual result)| Item | Details |
|---|---|
| Document type | Financial Results Presentation |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | 212 Millions of yen (YoY +21.1%) |
| Operating profit | -1,081 Millions of yen |
| Ordinary income | -1,028 Millions of yen |
| Net income | -1,022 Millions of yen |
| Gross Profit Margin | 61.3% (year-on-year change in percentage points: not disclosed) |
| Operating profit margin | -509.9% (year-on-year change in percentage points: not disclosed) |
| Selling, general and administrative expenses | 1,211 Millions of yen |
| Full-year earnings forecast | Fiscal year ending March 2027 Net Sales Not disclosed / Operating loss -1,430 / Ordinary loss -1,400 / Net loss attributable to owners of the parent -1,390 |
| Segment results | Not disclosed (only an explanation that CDMO business sales increased) |
| Breakdown of Factors Affecting the Change | Factors Increase in CDMO business sales / Amount Not disclosed, Factors Increase in R&D expenses / Amount 300 Millions of yen, Factors Increase in personnel expenses / Amount 115 Millions of yen, Factors Increase in non-operating income / Amount 45 Millions of yen, Factors Decrease in non-operating expenses / Amount 58 Millions of yen |
| Key KPIs | 76.1 ％, 91.6 ％, 75 Example |
| Financial targets | Not disclosed (equity ratio of 91.6% is an actual result) |
| Key points of the Q&A | Not disclosed (responses to advance questions are scheduled to be provided in the earnings presentation video) |
| New initiatives | Revision of the ReHeart earnings forecast after the drug price is determined, Acceleration of joint catheter development with 朝日インテック, Launch of research and development on an arrhythmia risk analysis platform with Institute of Science Tokyo, Preparation for physician-initiated clinical trials for the YS series, Research and development of large-scale cell culture technology using a METI subsidy for regenerative medicine CDMO operations, Launch of process development operations at a pilot-scale plant |
Items this document does not state (15)
Results for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / Share
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in revenue was due to higher sales in the CDMO business. The wider operating loss was due to higher research and development expenses, including preclinical trial costs associated with joint research with Stanford University, as well as higher personnel costs. Revenue for the fiscal year ending March 2027 was not disclosed because the drug price for the ReHeart product had not been determined.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.